| Literature DB >> 27814242 |
Dries S Martens1, Sandra Gouveia, Narjes Madhloum, Bram G Janssen, Michelle Plusquin, Charlotte Vanpoucke, Wouter Lefebvre, Bertil Forsberg, Malin Nording, Tim S Nawrot.
Abstract
BACKGROUND: As part of the lipidome, oxylipins are bioactive lipid compounds originating from oxidation of different fatty acids. Oxylipins could provide a new target in the developmental origins model or the ability of early life exposure to change biology.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27814242 PMCID: PMC5381981 DOI: 10.1289/EHP291
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
Figure 1Metabolic scheme of targeted oxylipins. Oxylipin synthesis via different biosynthetic pathways, COX, 5-LOX, 12/15-LOX, and CYP from their corresponding precursor fatty acids, arachidonic acid, eicosapentaenoic acid, dihomo-γ-linolenic acid, and linoleic acid (Zivkovic et al. 2012). All shown metabolites were targeted except for 5-HPETE (5-hydroperoxy-eicosatetraenoic acid), LTA4 (Leukotriene A4), and PGH2 (prostaglandin H2) and classified by biosynthetic pathway. Nondetectable targeted oxylipins (17-HDoDE, Resolvin D1, and Resolvin D2) are not shown on the scheme. A list of full metabolite names is provided in Table S4.
Characteristics of mother–newborn pairs (n = 197) selected from the ENVIRONAGE birth cohort between February 2010 and April 2014.
| Characteristic | Mean ± SD or |
|---|---|
| Maternal | |
| Age (years) | 29.1 ± 4.8 |
| Education | |
| Low | 27 (13.7) |
| Middle | 76 (38.6) |
| High | 94 (47.7) |
| Smoking status | |
| Never-smoker | 137 (69.5) |
| Stopped smoking before pregnancy | 44 (22.4) |
| Continued smoking during pregnancy | 16 (8.1) |
| Alcohol consumption during pregnancy | |
| No | 167 (84.8) |
| Pregestational BMI (kg/m2) | 23.8 ± 4.7 |
| Parity | |
| 1 | 111 (56.4) |
| 2 | 66 (33.5) |
| ≥ 3 | 20 (10.1) |
| Cesarean section | 7 (3.6) |
| Pregnancy complications | |
| Gestational diabetes | 11 (5.6) |
| Hypertension | 3 (1.5) |
| Hypo-/hyperthyroidism | 1 (0.5) |
| Infection | 3 (1.5) |
| Newborn | |
| Gender | |
| Boys | 108 (54.8) |
| Ethnicity | |
| European-Caucasian | 168 (85.3) |
| Gestational age (weeks) | 39.3 ± 1.4 |
| Apgar score 5 min after birth | |
| 7 | 3 (1.5) |
| 8 | 15 (7.6) |
| 9 | 61 (31.0) |
| 10 | 118 (59.9) |
| Season of delivery | |
| Winter | 59 (30) |
| Spring | 37 (19) |
| Summer | 52 (26) |
| Autumn | 49 (25) |
| pH artery cord blood | 7.3 ± 0.07 |
| Birth weight (g) | 3453.6 ± 420.7 |
| Total cholesterol (mg/dL) | 69.0 ± 18.0 |
| HDL level (mg/dL) | 30.6 ± 10.8 |
| Complete data for all variables except for pH artery cord blood ( | |
Outdoor PM2.5 (μg/m3) exposure characteristics for the 197 mothers included in this study from the ENVIRONAGE birth cohort.
| Exposure window | Mean ± SD | 25th percentile | 75th percentile |
|---|---|---|---|
| Trimester 1 | 15.5 ± 5.4 | 11.4 | 19.9 |
| Trimester 2 | 15.4 ± 5.1 | 11.1 | 19.7 |
| Trimester 3 | 16.1 ± 5.2 | 12.0 | 19.8 |
| Entire pregnancy | 15.7 ± 2.6 | 13.5 | 17.5 |
Figure 2Unadjusted Pearson correlation plots with 95% confidence intervals between oxylipin pathways and PM2.5 exposure during the second trimester: (A) correlation with the 5-LOX pathway and (B) correlation with the 12/15-LOX pathway. PC1, first principal component.
Figure 3Association between oxylipin biosynthetic pathways and in utero PM2.5 exposure during different time windows. Estimates are presented for each 5-μg/m3 increase in PM2.5. Models were adjusted for gestational age, pregestational BMI, maternal age, maternal smoking status, maternal education, newborn gender, cord blood total cholesterol and HDL levels, batch, and sample storage time. Trimester-specific windows were additionally adjusted for the other PM2.5 exposure windows (trimesters). Q indicates the multiple testing adjusted p-values using the Benjamini–Hochberg procedure.
Sensitivity analyses for the 5-LOX and 12/15-LOX pathways in association with in utero PM2.5 exposure.
| Analysis | Trimester 1 PM2.5 | Trimester 2 PM2.5 | Trimester 3 PM2.5 | Entire pregnancy PM2.5 | ||||
|---|---|---|---|---|---|---|---|---|
| β (95% CI) | β (95% CI) | β (95% CI) | β (95% CI) | |||||
| 5-LOX | ||||||||
| Main model | 0.05 (–0.25, 0.35) | 0.73 | 0.29 (0.07, 0.52) | 0.01 | 0.13 (–0.18, 0.45) | 0.41 | 0.64 (0.16, 1.12) | 0.01 |
| Apparent temperature adjusted | 0.02 (–0.40, 0.44) | 0.93 | 0.28 (0.01, 0.55) | 0.04 | 0.12 (–0.26, 0.50) | 0.53 | 0.67 (0.14, 1.19) | 0.01 |
| NO2 adjusted | –0.12 (–0.62, 0.37) | 0.62 | 0.32 (–0.02, 0.67) | 0.06 | 0.30 (–0.12, 0.72) | 0.16 | 0.70 (0.06, 1.33) | 0.03 |
| Single-trimester PM2.5 | –0.01 (–0.23, 0.21) | 0.94 | 0.30 (0.08, 0.52) | 0.008 | 0.11 (–0.12, 0.34) | 0.35 | NA | NA |
| Boys ( | –0.06 (–0.47, 0.35) | 0.78 | 0.34 (0.03, 0.65) | 0.03 | 0.12 (–0.29, 0.53) | 0.57 | 0.65 (0.00, 1.30) | 0.05 |
| Girls ( | 0.38 (–0.18, 0.93) | 0.18 | 0.31 (–0.06, 0.68) | 0.10 | 0.31 (–0.25, 0.88) | 0.28 | 0.98 (0.21, 1.75) | 0.01 |
| Not adjusted for gestational age | 0.06 (–0.24, 0.35) | 0.71 | 0.29 (0.07, 0.51) | 0.01 | 0.14 (–0.17, 0.44) | 0.38 | 0.63 (0.16, 1.11) | 0.009 |
| Excluding pregnancy complications and C‑sections ( | 0.09 (–0.23, 0.41) | 0.58 | 0.27 (0.04, 0.50) | 0.02 | 0.18 (–0.14, 0.51) | 0.27 | 0.66 (0.17, 1.15) | 0.009 |
| Excluding TriHOMEs and LTB4 | 0.04 (–0.24, 0.31) | 0.80 | 0.26 (0.06, 0.47) | 0.01 | 0.03 (–0.26, 0.31) | 0.86 | 0.52 (0.08, 0.95) | 0.02 |
| 12/15-LOX | ||||||||
| Main model | –0.14 (–0.60, 0.32) | 0.55 | 0.50 (0.15, 0.84) | 0.005 | –0.23 (–0.71, 0.24) | 0.34 | 0.70 (–0.04, 1.44) | 0.06 |
| Apparent temperature adjusted | –0.34 (–0.98, 0.30) | 0.30 | 0.38 (–0.03, 0.78) | 0.07 | –0.03 (–0.60, 0.55) | 0.92 | 0.64 (–0.16, 1.44) | 0.12 |
| NO2 adjusted | –0.44 (–1.19, 0.31) | 0.25 | 0.56 (0.04, 1.08) | 0.03 | –0.19 (–0.83, 0.46) | 0.57 | 0.83 (–0.15, 1.82) | 0.10 |
| Single-trimester PM2.5 | 0.05 (–0.29, 0.39) | 0.77 | 0.47 (0.13, 0.81) | 0.007 | –0.11 (–0.46, 0.25) | 0.56 | NA | NA |
| Boys ( | –0.24 (–0.91, 0.42) | 0.47 | 0.56 (0.06, 1.06) | 0.03 | –0.08 (–0.76, 0.59) | 0.81 | 0.78 (–0.27, 1.84) | 0.14 |
| Girls ( | –0.03 (–0.79, 0.73) | 0.93 | 0.52 (0.01, 1.03) | 0.04 | –0.40 (–1.17, 0.37) | 0.31 | 0.91 (–0.18, 1.99) | 0.10 |
| Not adjusted for gestational age | –0.08 (–0.54, 0.37) | 0.72 | 0.48 (0.13, 0.82) | 0.007 | –0.17 (–0.65, 0.30) | 0.47 | 0.73 (0.00, 1.47) | 0.05 |
| Excluding pregnancy complications and C‑sections ( | –0.08 (–0.59, 0.42) | 0.74 | 0.46 (0.10, 0.82) | 0.01 | –0.12 (–0.62, 0.39) | 0.65 | 0.74 (–0.02, 1.51) | 0.06 |
| Excluding 12-oxoETE | –0.14 (–0.59, 0.32) | 0.56 | 0.48 (0.14, 0.82) | 0.007 | –0.23 (–0.71, 0.24) | 0.34 | 0.67 (–0.07, 1.40) | 0.08 |
| Beta-coefficients are presented for each 5-μg/m3 increase in PM2.5. Unless otherwise indicated, all models were adjusted for gestational age, pregestational BMI, maternal age, maternal smoking status, maternal education, newborn gender, cord blood total cholesterol and HDL levels, batch, and sample storage time. | ||||||||
Estimated percent difference in individual metabolite concentration (nM) from the 5-LOX and 12/15-LOX pathways in association with in utero PM2.5 exposure.
| Pathway/metabolite | Loading on first PC | Trimester 2 PM2.5 | Entire pregnancy PM2.5 | ||
|---|---|---|---|---|---|
| % difference (95% CI) | % difference (95% CI) | ||||
| 5-LOX | |||||
| 5-HETE | 0.62 | 11.7 (1.4, 23.1) | 0.03 | 22.5 (–0.4, 50.7) | 0.05 |
| 5-oxoETE | 0.61 | 20.3 (1.7, 42.4) | 0.03 | 66.0 (16.2, 137.3) | 0.006 |
| 9(S)-HODE | 0.76 | 11.9 (–0.3, 25.6) | 0.06 | 17.2 (–8.4, 50.0) | 0.20 |
| LTB4 | 0.05 | –1.8 (–13.2, 11.0) | 0.77 | 3.0 (–20.9, 34.2) | 0.82 |
| 9,10,13-TriHOME | 0.76 | 8.5 (–3.2, 21.5) | 0.16 | 24.6 (–2.2, 58.9) | 0.08 |
| 9,12,13-TriHOME | 0.81 | 9.5 (–1.7, 21.9) | 0.10 | 25.6 (–0.2, 58.0) | 0.05 |
| 12/15-LOX | |||||
| 8-HETE | 0.83 | 15.3 (2.4, 29.8) | 0.02 | NA | NA |
| 9-HETE | 0.31 | 16.1 (–8.8, 47.7) | 0.22 | NA | NA |
| 11-HETE | 0.93 | 14.0 (2.3, 27.1) | 0.02 | NA | NA |
| 12-HETE | 0.83 | 28.7 (4.7, 58.2) | 0.02 | NA | NA |
| 12(S)-HEPE | 0.63 | 27.9 (4.7, 56.2) | 0.02 | NA | NA |
| 12-oxoETE | 0.55 | 49.7 (3.2, 117.1) | 0.03 | NA | NA |
| 15-HETE | 0.90 | 16.3 (4.5, 29.4) | 0.006 | NA | NA |
| 15(S)-HETrE | 0.88 | 15.7 (0.8, 32.7) | 0.04 | NA | NA |
| 15-oxoETE | 0.64 | 10.3 (–3.9, 26.7) | 0.16 | NA | NA |
| 13-HODE | 0.81 | 11.4 (–0.2, 24.3) | 0.05 | NA | NA |
| 13-oxoODE | 0.59 | 8.0 (–5.8, 23.8) | 0.27 | NA | NA |
| first PC, first principal component. | |||||